drugset / Trial / NCT02953847
The Bioavailability of Rifampicin in (FDCs) Widely Used in South Africa to Treat Drug-susceptible (TB)
RandomizedCrossoverOpen-labelOther
Summary
3-way cross-over single dose design evaluating bioavailability of 2 rifampicin-containing FDCs vs a single drug comparator in healthy volunteers
Timeline
- Start
- 2016-11
- Primary completion
- 2017-02
- Completion
- 2017-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifafour e-275 | Unknown | 75 mg | — |
| Subject | Rifafour e-275 | Unknown | 150 mg | — |
| Subject | Rifafour e-275 | Unknown | 275 mg | — |
| Subject | Rifafour e-275 | Unknown | 400 mg | — |
| Subject | Rifampin | Small molecule | 150 mg | — |
| Subject | Rimactazid | Unknown | 75 mg | — |
| Subject | Rimactazid | Unknown | 150 mg | — |